Insights On Drug Development

  1. Mass Spectrometry From Discovery To Launch 1/21/2026

    Mass spectrometry is now a fast, sensitive tool that supports drug discovery, development, quality control, and lifecycle management through detailed molecular analysis.

  2. Designing Cell Therapy Analytical Programs For Regulatory Success 1/20/2026

    Expedited cell therapy pathways demand early, reliable analytical development to ensure robust data, regulatory confidence, and smooth transitions from discovery through clinical stages without costly delays.

  3. Assessing Developability And Designing Advanceable Formulations From The Start 1/15/2026

    Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.

  4. Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development 1/15/2026

    Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

  5. Improving Swallowing And Palatability With Patient‑Friendly Forms 1/15/2026

    Improve medication adherence and health outcomes by developing patient-friendly dosage forms that enhance swallowability and palatability for pediatric, geriatric, and dysphagic populations.

  6. Formulation Development Experience For Effective Particle Identification 1/14/2026

    Combining advanced analytics with deep formulation knowledge enables precise root-cause analysis, preventing manufacturing delays and ensuring that products remain high-quality and safe for patients.

  7. T3P – A Green Solution For Peptide Coupling, Water Removal Reactions 1/13/2026

    The session focuses on the use of T3P (propanephosphonic acid anhydride) in amidation and peptide coupling reactions, including both liquid-phase and solid-phase peptide synthesis.

  8. Increase Agility By Integrating Drug Substance And Drug Product 1/9/2026

    Biopharma success depends on agility. Move efficiently from discovery to delivery by co-locating drug substance and drug product operations, reducing transfer risks and accelerating your timeline

  9. Optimizing Bispecific Antibody Expression Via Multi-Omics Analysis And Vector Redesign 12/17/2025

    Discover how diagnosing ribosome pausing sites and optimizing codon usage dramatically improves bispecific antibody titers, turning difficult-to-express candidates into viable therapeutics.

  10. Doubling Up For Speed In Biomanufacturing 12/12/2025

    Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.